Theolytics
THEO-260 Clinical Trial
A new approach for ovarian cancer
Innovation in ovarian cancer treatment
If you or someone you know is living with ovarian cancer that is no longer responding to platinum-based treatments, this study may be an option.
About the study
THEO-260 is an investigational therapy chosen for its ability to target cancer directly within the abdominal cavity, where ovarian cancer typically spreads.
How treatment is given
THEO-260 is given directly into the abdomen using a small device. Treatment takes place over two weeks.
Costs and coverage
THEO-260 is provided at no cost. Some study-related tests are covered, while routine care may be billed to you or your insurance.
What participation involves
If you take part in this study, you can expect:
01
A screening period to confirm eligibility
02
Placement of an intraperitoneal port for drug delivery
03
A short treatment period with scheduled dosing visits
04
Follow-up monitoring visits
Who may be eligible?
Women 18 years or older diagnosed with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Treatment history: cancer that is no longer responding to platinum-based treatment.
No placebo: all participants receive THEO-260
Study Details
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients | Trial ID: NCT07211659 | Website: ClinicalTrials.gov ↗